WuXi Biologics Sets Standards with CDP's Top Ratings
WuXi Biologics has recently achieved remarkable recognition by being included on the CDP "A" lists for both Climate Change and Water Security for 2025. This recognition highlights the company's dedication to environmental stewardship and transparent practices.
Climate Change Leadership
Being awarded an "A" rating by CDP signifies WuXi Biologics' pivotal role in environmental performance. The company’s climate strategy is a comprehensive plan aimed at reaching net-zero emissions across its value chain by 2050, as validated by the Science Based Targets initiative (SBTi). To achieve this ambitious goal, WuXi Biologics has established a detailed roadmap entailing various initiatives such as enhancing energy efficiency, optimizing processes, and integrating renewable energy solutions. A remarkable highlight is that their biologics facility in Ireland now operates entirely on renewable electricity.
Focused Initiatives for a Sustainable Future
WuXi Biologics has implemented several robust initiatives to back its climate goals. These initiatives not only showcase the company's commitment to reducing its carbon footprint but also aim at educating and engaging stakeholders on the importance of sustainability. They have also been actively seeking partnerships in the industry to foster collective action against climate change.
Water Security Excellence
In addition to its climate efforts, WuXi Biologics has been recognized for the third consecutive year on the CDP Water Security "A" List. It has developed an extensive framework for water management that aligns with the United Nations Sustainable Development Goal 6 (SDG 6). The company has set an ambitious target to reduce water consumption intensity by 30% by 2025 compared to a 2019 baseline.
Commitment to Water Stewardship
To further its dedication to water security, WuXi Biologics has launched a Water Excellence Stewardship (WES) program that addresses crucial topics such as water governance, water balance, and water quality. Through WES, the company is committed to promoting safe water practices within its operations and beyond, emphasizing environmental and personal hygiene.
Recognition and Collaboration
Earlier this year, WuXi Biologics achieved an "A" rating in the CDP's Supplier Engagement assessment. This acknowledges their efforts to drive climate action throughout their value chain. The company not only pursues its own climate objectives but also collaborates with global suppliers to facilitate the transition to a sustainable economy. This is achieved through a comprehensive sustainable supply chain management system and diligent tracking of Scope 3 emissions.
Leadership Commitment
Dr. Chris Chen, the CEO of WuXi Biologics, expressed gratitude for the dual "A" ratings, stating, "This recognition reflects our unwavering commitment to addressing Climate Change and Water Security. As a leader in green biologics Contract Research, Development and Manufacturing Organization (CRDMO), we feel a strong responsibility to push the industry toward a more sustainable future."
WuXi Biologics and Global Initiatives
As a proactive member of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics endorses sustainability initiatives widely. The company holds various accolades, including an MSCI AAA Rating and an EcoVadis Platinum Medal, signaling its commitment to excellence in Environmental, Social, and Governance (ESG) practices.
Moreover, WuXi Biologics has been recognized in several sustainability indices, such as the Dow Jones Sustainability Indices and the Hang Seng ESG 50 Index, showcasing its dedication to minimal environmental risk and sustained responsible practices over the years.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) stands out as a preeminent global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides comprehensive solutions designed to assist partners in every stage from discovery through to the manufacturing of biologics.
With a talented workforce exceeding 12,000 across key global locations, including China, the United States, and Europe, the company utilizes its advanced technologies to deliver efficient and cost-effective biologics solutions. As of mid-2025, WuXi Biologics manages 864 integrated client projects, of which 24 are in the commercial manufacturing phase.
Prioritizing sustainability, WuXi Biologics continuously innovates green technologies, delivering advanced and eco-friendly CRDMO solutions while championing societal and environmental contributions. They are dedicated to fostering responsible practices throughout their entire value chain, ensuring mutually beneficial results for stakeholders.
Frequently Asked Questions
What recognition has WuXi Biologics received regarding sustainability?
WuXi Biologics has been recognized by CDP with "A" ratings for Climate Change and Water Security, highlighting its leadership in environmental initiatives.
What are WuXi Biologics' goals for climate impact?
The company aims to achieve net-zero emissions across its value chain by 2050, with a clear roadmap and various sustainability initiatives in place.
How does WuXi Biologics manage water resources?
WuXi Biologics has implemented a framework for water management aligned with UN SDG 6, aiming for a 30% reduction in water consumption intensity by 2025.
What is the significance of the Water Excellence Stewardship program?
This program focuses on responsible water governance, ensuring the company promotes environmental and personal hygiene while effectively managing water resources.
How many projects does WuXi Biologics currently support?
As of mid-2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.
